Securities Suit Filed Over Zoetis Alleged Failure to Disclose Weakening Sales of Key Pet Drugs
Plaintiff firms say undisclosed declines in vet adoption after FDA safety warnings could have misled investors and are soliciting class members ahead of a July 27, 2026 lead-plaintiff deadline.
Overview
- Two plaintiff firms have filed a securities class action against Zoetis claiming the company misled investors about companion-animal product performance during the alleged class period from January 14, 2025 through May 6, 2026.
- The complaint says Librela uptake fell as veterinarians grew cautious after FDA safety communications about serious neurological complications, and that Zoetis’ Simparica Trio, Apoquel and Cytopoint lost market share to lower-priced or newly launched competitors.
- Plaintiff firms The Law Offices of Frank R. Cruz and Rosen Law Firm are publicly soliciting Zoetis investors to join the suit and to move for lead-plaintiff status by July 27, 2026.
- No class has been certified and the case remains at an early procedural stage, meaning investors are not represented by court-appointed counsel unless they retain one now.
- If the court eventually finds the alleged nondisclosures were material, the lawsuit seeks damages tied to the dates when the omitted information became public, and the litigation could affect future reporting and investor scrutiny of FDA-driven product risks.